-
Mashup Score: 5CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir - 1 day(s) ago
Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment’s enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 13 day(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
-
Mashup Score: 1TPST-1120 Plus Nivolumab Offers New Treatment Potential in RCC - 14 day(s) ago
The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Unmeet Needs in Non-Clear Cell Renal Cell Carcinoma - 16 day(s) ago
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Unmeet Needs in Non-Clear Cell Renal Cell Carcinoma - 23 day(s) ago
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Chromophobe Renal Cell Carcinoma - Beyond the Abstract - 27 day(s) ago
renal cell carcinomas (vhRCCs), clear cell renal cell carcinoma (ccRCC), renal cell carcinoma (RCC), kidney cancer, vacuolar ATPase (v-ATPase), Tuberous Sclerosis Complex (TSC), mechanistic target of rapamycin complex 1 (mTORC1), innate lymphoid cells type 1 (ILC1s), mTOR pathways, PTEN mutations, Birt-Hogg-Dube syndrome (BHD).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Delve into the intricate world of Chromophobe #RCC with our latest review! Discover the unique pathogenic mechanisms, potential therapeutic targets, and challenges in advancing research and treatment with Elizabeth Henske and Melissa Daou @BrighamWomens > https://t.co/AevweMyNAH https://t.co/Q3Fi9n6al1
-
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 1 month(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
-
Mashup Score: 4
Over the last 20 years, standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have progressed from cytokines and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) to immune checkpoint inhibition (ICI)–based treatment. The availability of these , however, can vary worldwide.
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet-
Chatted w/ @medpagetoday on our @JCOGO_ASCO study on the evolution of systemic #RCC therapy in Canada, highlighting the levers in public health care systems https://t.co/mhEQDRIGf3 Yeoman effort by @luisamcardenas w/ @UroOncMD @DrDanielHeng @nbasappaCCI @SiTanguay & many! 👏 🙏 https://t.co/vcYJtKrKIi https://t.co/3dttBJAVuD
-
-
Mashup Score: 0Chromophobe Renal Cell Carcinoma - Beyond the Abstract - 2 month(s) ago
renal cell carcinomas (vhRCCs), clear cell renal cell carcinoma (ccRCC), renal cell carcinoma (RCC), kidney cancer, vacuolar ATPase (v-ATPase), Tuberous Sclerosis Complex (TSC), mechanistic target of rapamycin complex 1 (mTORC1), innate lymphoid cells type 1 (ILC1s), mTOR pathways, PTEN mutations, Birt-Hogg-Dube syndrome (BHD).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Delve into the intricate world of Chromophobe #RCC with our latest review! Discover the unique pathogenic mechanisms, potential therapeutic targets, and challenges in advancing research and treatment with Elizabeth Henske and Melissa Daou @BrighamWomens > https://t.co/AevweMyNAH https://t.co/Q3Fi9n6al1
-
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 2 month(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
CheckMate-214 at 8 years: Nivolumab + ipilimumab shows durable survival benefit in advanced #RCC. Nizar Tannir, MD, FACP @MDAndersonNews joins @PBarataMD @caseccc to discuss 8yr results in this conversation on UroToday > https://t.co/GnTt5WpIEA https://t.co/MHaEddMoI1